{"id":497427,"date":"2020-07-21T13:44:01","date_gmt":"2020-07-21T13:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=497427"},"modified":"2020-07-21T13:44:01","modified_gmt":"2020-07-21T13:44:01","slug":"fragile-x-syndrome-market-size-share-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/fragile-x-syndrome-market-size-share-trends-epidemiology-forecast-till-2030_497427.html","title":{"rendered":"Fragile X Syndrome Market, Size, Share, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Fragile X Syndrome Market, Size, Share, Trends, Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Fragile X Syndrome Market, Size, Share, Trends, Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Fragile X Syndrome (FXS) , historical and forecasted epidemiology as well as the Fragile X Syndrome (FXS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">Fragile X Syndrome (FXS) is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3; which leads to an hyper-methylated region in the gene promoter therefore silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epidemiology Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The total cases of Fragile X Syndrome (FXS) in 7MM in 2017 was 117,962&nbsp;<\/li>\n<li>&nbsp;The gender-specific prevalent cases of Fragile X Syndrome (FXS) in the US in 2017&nbsp;<\/li>\n<ul>\n<li>40,102 &#8211; Males<\/li>\n<li>27,552 &ndash; Females<\/li>\n<li>The diagnosed prevalent cases of Fragile X Syndrome in the United States in 2017 was 67,654<\/li>\n<li>The prevalent population of FXS in Japan in 2017 was 12,645&nbsp;<\/li>\n<\/ul>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Market Insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/fragile-x-syndrome-fxs-market\" target=\"_blank\">Fragile X Syndrome market size in 7MM in 2017 was USD 33.8 Million&nbsp;<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/8abce506d0a83060f56555c1fcdba0c0.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/fragile-x-syndrome-fxs-market\" target=\"_blank\">Fragile X Syndrome<\/a> Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Funding and cooperation of various organizations<\/li>\n<li>Identifying potential targets by animal models<\/li>\n<li>Development of novel therapies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Fragile X Syndrome Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Failure of Clinical Trials<\/li>\n<li>Disease Burden<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Key benefits of the report<\/p>\n<p style=\"text-align: justify;\">1. Fragile X Syndrome market report covers a descriptive overview and comprehensive insight of the Fragile X Syndrome epidemiology and Fragile X Syndrome market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<br \/>2. Fragile X Syndrome market report provides insights into the current and emerging therapies.<br \/>3. Fragile X Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.<br \/>4. Fragile X Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Fragile X Syndrome market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Key Insights<\/strong><br \/><strong>2. Executive summary<\/strong><br \/><strong>3. Organisations<\/strong><br \/><strong>4. Fragile X Syndrome Epidemiology and Market Methodology<\/strong><br \/><strong>5. Fragile X Syndrome Market Overview at a Glance<\/strong><br \/><strong>6. Fragile X Syndrome Disease Background and Overview<\/strong><br \/><strong>7. Fragile X Syndrome Epidemiology and Patient Population<\/strong><br \/><strong>7.1. Key Findings<\/strong><br \/><strong>7.2. Total Diagnosed Prevalent cases of Fragile X Syndrome in 7MM<\/strong><br \/><strong>7.3. United States<\/strong><br \/><strong>7.4. EU5<\/strong><br \/><strong>7.5. Assumptions and Rationale<\/strong><br \/><strong>7.6. Germany<\/strong><br \/><strong>7.7. France<\/strong><br \/><strong>7.8. Italy<\/strong><br \/><strong>7.9. Spain<\/strong><br \/><strong>7.10. United Kingdom (UK)<\/strong><br \/><strong>7.11. Japan<\/strong><br \/><strong>8. Fragile X Syndrome Current Treatment<\/strong><br \/><strong>9. Unmet Need<\/strong><br \/><strong>10. Fragile X Syndrome Emerging Drugs<\/strong><br \/><strong>10.1. Key Cross Competition<\/strong><br \/><strong>10.2. Cannabidiol: Zynerba Pharmaceuticals<\/strong><br \/><strong>10.3. Acamprosate: Confluence Pharmaceuticals<\/strong><br \/><strong>10.4. BPN14770: Tetra Therapeutics<\/strong><br \/><strong>10.5. OV101: Ovid Therapeutics<\/strong><br \/><strong>10.6. Trofinetide: Neuren Pharmaceuticals<\/strong><br \/><strong>11. Fragile X Syndrome Market Size<\/strong><br \/><strong>12. Fragile X Syndrome Market Outlook: 7 MM<\/strong><br \/><strong>12.1. United States<\/strong><br \/><strong>12.2. EU5<\/strong><br \/><strong>12.3. Germany<\/strong><br \/><strong>12.4. France<\/strong><br \/><strong>12.4.3. Italy<\/strong><br \/><strong>12.5. Spain<\/strong><br \/><strong>12.6. United Kingdom<\/strong><br \/><strong>12.7. Japan<\/strong><br \/><strong>13. Market Drivers<\/strong><br \/><strong>14. Market Barriers<\/strong><br \/><strong>15. SWOT analysis<\/strong><br \/><strong>16. Cases studies<\/strong><br \/><strong>17. KOL Views<\/strong><br \/><strong>18. Appendix<\/strong><br \/><strong>19. DelveInsight Capabilities<\/strong><br \/><strong>20. Disclaimer<\/strong><br \/><strong>21. About DelveInsight<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=fragile-x-syndrome-market-size-share-trends-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=fragile-x-syndrome-market-size-share-trends-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Fragile X Syndrome (FXS) , historical and forecasted epidemiology as well as the Fragile X Syndrome (FXS) market trends &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/fragile-x-syndrome-market-size-share-trends-epidemiology-forecast-till-2030_497427.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-497427","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/497427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=497427"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/497427\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=497427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=497427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=497427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}